Apogee Therapeutics Inc (APGE)

Jun 17, 2025

Rhumbline Advisers Has $2.03 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

Jun 17, 2025

Jun 17, 2025

Contrasting argenx (NASDAQ:ARGX) and Apogee Therapeutics (NASDAQ:APGE) - Defense World

Jun 17, 2025

Jun 16, 2025

APGE Stock Update: Apogee Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com

Jun 16, 2025

Jun 16, 2025

Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Average Recommendation of “Buy” by Brokerages - Defense World

Jun 16, 2025

Jun 11, 2025

Apogee Therapeutics stock maintains buy rating ahead of key trial data - Investing.com Canada

Jun 11, 2025

Jun 11, 2025

Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by California State Teachers Retirement System - Defense World

Jun 11, 2025

Jun 09, 2025

Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? - sharewise

Jun 09, 2025

Jun 06, 2025

Insider Sell: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) - GuruFocus

Jun 06, 2025

Jun 06, 2025

Ameriprise Financial Inc. Makes New $259,000 Investment in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

Jun 06, 2025

May 29, 2025

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference - GlobeNewswire

May 29, 2025

May 29, 2025

4,824 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by BNP Paribas Financial Markets - Defense World

May 29, 2025

May 29, 2025

Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Bank of America Corp DE - Defense World

May 29, 2025

May 28, 2025

Millennium Management LLC Has $5.90 Million Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

May 28, 2025

May 27, 2025

(APGE) Investment Analysis and Advice - news.stocktradersdaily.com

May 27, 2025

May 27, 2025

Stifel maintains Buy rating, $35 target on Apogee Therapeutics stock By Investing.com - Investing.com India

May 27, 2025

May 27, 2025

Stifel maintains Buy rating, $35 target on Apogee Therapeutics stock - Investing.com

May 27, 2025

May 27, 2025

D. E. Shaw & Co. Inc. Has $445,000 Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

May 27, 2025

May 26, 2025

Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World

May 26, 2025

May 25, 2025

Deutsche Bank AG Boosts Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

May 25, 2025

May 25, 2025

Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $94.60 - Defense World

May 25, 2025

May 22, 2025

Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet - MSN

May 22, 2025

May 20, 2025

Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - GlobeNewswire

May 20, 2025

May 17, 2025

How To Trade (APGE) - news.stocktradersdaily.com

May 17, 2025

May 16, 2025

Northern Trust Corp Grows Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

May 16, 2025

May 15, 2025

Q1 Earnings Forecast for APGE Issued By Wedbush - Defense World

May 15, 2025

May 15, 2025

Wedbush Equities Analysts Lift Earnings Estimates for APGE - Defense World

May 15, 2025

May 13, 2025

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma - marketscreener.com

May 13, 2025

May 13, 2025

Apogee Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 13, 2025

May 12, 2025

Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class (APGE) - Seeking Alpha

May 12, 2025

May 12, 2025

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results - GlobeNewswire

May 12, 2025

May 12, 2025

BTIG maintains Apogee Therapeutics stock Buy rating, $100 target By Investing.com - Investing.com India

May 12, 2025

May 12, 2025

BTIG maintains Apogee Therapeutics stock Buy rating, $100 target - Investing.com

May 12, 2025

May 12, 2025

Why Is Apogee Therapeutics Stock Trading Higher On Monday? - Benzinga

May 12, 2025

May 12, 2025

Apogee Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025

May 12, 2025

Apogee Therapeutics reports positive results from asthma treatment trial - Seeking Alpha

May 12, 2025

May 12, 2025

Apogee Therapeutics (APGE) Reports Promising Phase 1b Trial Resu - GuruFocus

May 12, 2025

May 12, 2025

Apogee (APGE) Sets Sights on Transformative Achievements in 2025 - GuruFocus

May 12, 2025

May 12, 2025

Apogee Therapeutics Q1 Loss Widens - marketscreener.com

May 12, 2025

May 12, 2025

Apogee Therapeutics Reports Positive Phase 1b Trial Results - TipRanks

May 12, 2025

May 12, 2025

Apogee Therapeutics, Inc. SEC 10-Q Report - TradingView

May 12, 2025

May 12, 2025

Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 12, 2025

May 12, 2025

Earnings Flash (APGE) Apogee Therapeutics Posts Q1 Net Loss $55.3M, vs. FactSet Est of $72.3M Loss - marketscreener.com

May 12, 2025

May 12, 2025

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma - The Manila Times

May 12, 2025

May 12, 2025

Apogee Therapeutics Reports Positive Phase 1b Trial Results for APG808 in Asthma, Highlighting Durable FeNO Suppression and Potential for Extended Dosing Intervals - Nasdaq

May 12, 2025

May 10, 2025

Apogee Therapeutics (APGE) Projected to Post Quarterly Earnings on Monday - Defense World

May 10, 2025

May 10, 2025

Apogee Therapeutics chief medical officer sells shares totaling $97,418 By Investing.com - Investing.com Nigeria

May 10, 2025

May 09, 2025

Apogee Therapeutics chief medical officer sells shares totaling $97,418 - Investing.com Australia

May 09, 2025